LIF SOC LI Lidong Pei Eli Lilly’s Oral Weight-Loss Drug Foundayo Reports Phase III T2D Results: 16% Reduction in… On April 16, Eli Lilly and Company announced positive topline results from the Phase III ACHIEVE-4 trial of Foundayo (orforglipron), the…
